Salbutamol and ipratropium in partially reversible airway obstruction.
Thirty-six patients with a combination of reversible and persistent airway obstruction were treated with ipratropium bromide, salbutamol and a combination of both in high dose by nebulizer after a control period of rimiterol. The ipratropium and salbutamol were given double blind in random order and the dose of each was the same during the combination periods. Although there was a significant increase in pulmonary function in all treatment periods over the control, only the 6-minute walking distance was significantly improved in the combination period over treatment with salbutamol and ipratropium individually. This was not due to a progressive rise with time irrespective of the therapy. The results are compatible with a small number of patients benefiting from combination therapy.
D000328:Adult; D000420:Albuterol / Q000627:therapeutic use*; D001286:Atropine Derivatives / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D009241:Ipratropium / Q000627:therapeutic use*; D008173:Lung Diseases, Obstructive / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D005082:Physical Exertion; D012129:Respiratory Function Tests
D001286:Atropine Derivatives; D009241:Ipratropium; D000420:Albuterol